The Platform of Plasma Protein Users (PLUS) is a consortium of six patient organisations representing people living with treatable rare plasma-related disorders such as haemophilia, primary immunodeficiencies and alpha1 anti-trypsin deficiency among others. Together, these organisations represent the views of more than 110,000 people living with treatable rare plasma-related disorders in Europe.

PLUS represents organisations of patients with treatable rare diseases linked by common therapies based on products manufactured from human plasma.
We are of the firm view that as the end users of these vital therapies our voice as the major stakeholders should be given primacy in consultation with the EU Institutions on any matter related to relevant Directives and Guidelines and major issues relating to blood and plasma-derived products.